| Project/Area Number |
26893174
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
ANDO Hidenori 徳島大学, 大学院医歯薬学研究部, 特任助教 (00735524)
|
|---|
| Project Period (FY) |
2014-08-29 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | がん治療 / 悪性胸膜中皮腫 / 胃がん腹膜播種 / リポソーム / 抗がん剤 / 核酸 / ドラッグデリバリーシステム / 体腔内投与 / 胸腔内投与 / ペメトレキセド / DDS / 腹腔内投与 / 腹膜播種転移 |
|---|
| Outline of Final Research Achievements |
In the present study, we evaluated the potency of intrapleural or intraperitoneal direct administration of DDS therapeutics as novel therapeutic strategy for cancer that proliferates and invades in pleural or peritoneal cavity, e.g. malignant pleural mesothelioma (MPM) and peritoneal dissemination of gastric cancer. MPM model mice were prepared and were intrapleurally injected with liposomes encapsulating anti-cancer drugs or liposomes complexed with nucleic acids. As results, both liposome formulations showed intrapleural retention for an extended period of time and exerted high therapeutic effect on MPM.
|
